Cargando…

Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials

Tumor-associated macrophages (TAMs) exert integrated effects in all aspects of tumor progression, including tumor cell proliferation, angiogenesis, invasion, and metastasis. Recently, considerable preclinical and clinical trials have demonstrated that TAM-targeted therapy is an effective antitumor t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shuhang, Yang, Yuqi, Ma, Peiwen, Huang, Huiyao, Tang, Qiyu, Miao, Huilei, Fang, Yuan, Jiang, Ning, Li, Yandong, Zhu, Qi, Tao, Wei, Zha, Yan, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908037/ https://www.ncbi.nlm.nih.gov/pubmed/35317518 http://dx.doi.org/10.1016/j.omto.2022.02.019

Ejemplares similares

KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
por: Wang, Shuhang, et al.
Publicado: (2022)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

Targeting rare tumors: new focus for clinical research in China
por: Wang, Shuhang, et al.
Publicado: (2022)

Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development
por: Wang, Shuhang, et al.
Publicado: (2022)

CAR-macrophage: An extensive immune enhancer to fight cancer
por: Wang, Shuhang, et al.
Publicado: (2022)

Association between germ-line HLA and immune-related adverse events
por: Jiang, Ning, et al.
Publicado: (2022)

The current status and future of ADC therapy for small cell Lung Cancer: a promising approach
por: Zhou, Jiawei, et al.
Publicado: (2023)

Seven-year exclusivity and beyond for drugs of rare diseases in China
por: Jiang, Yale, et al.
Publicado: (2023)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

Microfluidic cell squeeze-based vaccine comes into clinical investigation
por: Wang, Shuhang, et al.
Publicado: (2023)

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
por: Chen, Kun, et al.
Publicado: (2022)

The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges
por: Huang, Huiyao, et al.
Publicado: (2022)

Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States
por: Huang, Huiyao, et al.
Publicado: (2022)

Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies
por: Wang, Shuhang, et al.
Publicado: (2020)

Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors
por: Wang, Shuhang, et al.
Publicado: (2021)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

Outcome measures of phase III anticancer drug trials in China
por: Guo, Lanwei, et al.
Publicado: (2023)

Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies
por: Su, Siyu, et al.
Publicado: (2022)

Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution
por: Huang, Huiyao, et al.
Publicado: (2023)

Evolution of Early-Phase Anticancer Drug Investigations in China
por: Wang, Shuhang, et al.
Publicado: (2022)

Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention
por: Dawei, Wu, et al.
Publicado: (2022)

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours
por: Wang, Shuhang, et al.
Publicado: (2021)

Bleomycin inhibits proliferation and induces apoptosis in TPC-1 cells through reversing M2-macrophages polarization
por: Liu, Hongwei, et al.
Publicado: (2018)

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
por: Zhang, Qian, et al.
Publicado: (2023)

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy
por: Wang, Shuhang, et al.
Publicado: (2021)

Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
por: Zhao, Guo, et al.
Publicado: (2023)

Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages
por: Hu, Weimin, et al.
Publicado: (2023)

Ferroptosis landscape in prostate cancer from molecular and metabolic perspective
por: Liang, Jiaming, et al.
Publicado: (2023)

The landscape perspective /
Publicado: (1995)

Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy
por: Xie, Qiang, et al.
Publicado: (2021)

Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape
por: Wang, Zide, et al.
Publicado: (2022)

Integrated proteomic and transcriptomic landscape of macrophages in mouse tissues
por: Qie, Jingbo, et al.
Publicado: (2022)

Corrigendum to “Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages” [Heliyon 9(3) (March 2023) e14272]
por: Hu, Weimin, et al.
Publicado: (2023)

Copper in cancer: from limiting nutrient to therapeutic target
por: Tang, Xiaolong, et al.
Publicado: (2023)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

The impact of screen time changes on anxiety during the COVID-19 pandemic: sleep and physical activity as mediators
por: Chen, Qiyu, et al.
Publicado: (2022)

FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes
por: Wang, Xiao, et al.
Publicado: (2021)

Landscape and progress of global COVID-19 vaccine development
por: Huang, Hui-Yao, et al.
Publicado: (2021)

Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer
por: Long, Fei, et al.
Publicado: (2021)

The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
por: Wang, Shuhang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v9r6atjb22fk8rl85fdr24lf7h